Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

The increase is driven by growth in oncology and cardiovascular, partially offset by declines in diabetes, vaccines, immunology, and virology. Merck's blockbuster cancer immunotherapy Keytruda ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

"An overwhelming body of scientific evidence, including more than 20 years of research and development, continues to support the safety and efficacy profiles of our HPV vaccines," Merck said in a ...

Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028. Merck stands to lose $62 billion over four years following the ...